

## Acute Lymphoblastic Leukemia FISH Panels

Acute lymphoblastic leukemia (ALL) is an aggressive leukemia of B- or T-lineage immature lymphoid cells. B-cell ALL (B-ALL) is primarily a disease of early childhood. Fluorescence in situ hybridization (FISH) testing identifies rearrangements in specific genes used in risk stratification and treatment decisions for children and adults newly diagnosed with B-ALL.

### Disease Overview

#### Incidence

B-ALL occurs in 1.6/100,000 individuals per year, and is the most common leukemia in childhood.<sup>1</sup>

#### Symptoms

Bone marrow failure (eg, anemia, thrombocytopenia, leukopenia) and constitutional symptoms (eg, fever, lethargy, weight loss) are common.<sup>2</sup> In children, joint or extremity pain may be the only presenting symptom.<sup>3,4</sup>

### Genetics

Pediatric ALL	Adult ALL	Ph-Like ALL
<i>BCR-ABL1</i>	<i>BCR-ABL1</i>	<i>CRLF2</i>
<i>KMT2A (MLL)</i>	<i>KMT2A (MLL)</i>	<i>JAK2</i>
<i>ETV6-RUNX1</i>	<i>TCF3 (E2A)</i>	<i>EPOR</i>
<i>CEP4</i>	<i>IGH</i>	<i>CSF1R</i>
<i>CEP10</i>	<i>MYC</i>	<i>ABL1</i>
		<i>ABL2</i>
		<i>PDGFRB</i>

Ph, Philadelphia chromosome

### Test Interpretation

#### Test Results

##### Pediatric FISH

- Normal: no evidence of *BCR-ABL1* t(9;22), *KMT2A (MLL)* rearrangement, *ETV6-RUNX1* t(12;21), *RUNX1* amplification or copy number gain with *CEP4* and/or *CEP10*
- Abnormal: one of the above rearrangements or translocations detected

##### Adult FISH

- Normal: no evidence of *BCR-ABL1* t(9;22), *KMT2A (MLL)* rearrangement, *TCF3 (E2A)* rearrangement, *IGH* rearrangement, or *MYC* rearrangement
- Abnormal: one of the above rearrangements/translocations or copy number change detected

### Tests to Consider

#### Acute Lymphoblastic Leukemia (ALL) Panel by FISH, Adult 2002647

**Method:** Fluorescence in situ Hybridization (FISH)

- Recommended FISH panel for adults with newly diagnosed B-ALL
- Probes include *BCR-ABL1* t(9;22), *KMT2A (MLL)* 11q23 rearrangement (partner not determined), *TCF3 (E2A)* rearrangement (partner not determined), *IGH* rearrangement (partner not determined), *MYC* rearrangement

#### Acute Lymphoblastic Leukemia (ALL) Panel by FISH, Pediatric 2002719

**Method:** Fluorescence in situ Hybridization (FISH)

- Recommended FISH panel for children with newly diagnosed B-ALL
- Probes include *BCR-ABL1* t(9;22), *KMT2A (MLL)* 11q23 rearrangement (partner not determined), *ETV6-RUNX1*, t(12;21), *CEP4*, *CEP10*

#### Ph-Like Acute Lymphoblastic Leukemia (ALL) Panel by FISH 3000455

**Method:** Fluorescence in situ Hybridization (FISH)

- Diagnosis, prognosis, and monitoring of *BCR-ABL1*-like B-ALL
- Probes include *CRLF2* rearrangement, *JAK2* rearrangement, *EPOR* rearrangement, *CSF1R* rearrangement, *ABL1* rearrangement, *ABL2* rearrangement, *PDGFRB* rearrangement
- Order when other major prognostic markers (eg, *BCR-ABL1*, *ETV6-RUNX1*) are negative

#### Testing Strategy

At diagnosis, the minimum ALL workup includes bone marrow aspirate for morphology, immunophenotyping, cytogenetics (eg, karyotyping and fluorescence in situ hybridization [FISH]), and other molecular testing, as indicated.

To order FISH probes individually, see [Chromosome FISH, Interphase 2002298](#).

See [Related Tests](#)

## Ph-Like ALL FISH

- Normal: no evidence of rearrangement involving *CRLF2*, *JAK2*, *EPOR*, *CSF1R*, *ABL1*, *ABL2*, or *PDGFRB*
- Abnormal: one of the described rearrangements detected

## Prognostic Issues

More information on the prognostic significance of identified genetic rearrangements can be found in the ARUP Consult [Acute Lymphoblastic Leukemia](#) topic.

## Limitations

Panels detect only the specific aberrations targeted by the FISH probes included. Chromosome alterations outside the regions complementary to these probes will not be detected.

## References

1. American Cancer Society. [Key statistics for acute lymphocytic leukemia](#). [Last revised: Jan 2020; Accessed: Jul 2020]
2. Terwilliger T, Abdul-Hay M. [Acute lymphoblastic leukemia: a comprehensive review and 2017 update](#). Blood Cancer J. 2017;7(6):e577. PubMed
3. National Comprehensive Cancer Network. [NCCN Clinical Practice Guidelines in Oncology, acute lymphoblastic leukemia](#), version 2.2019. [Accessed: Oct 2019]
4. Paul S, Kantarjian H, Jabbour EJ. [Adult Acute Lymphoblastic Leukemia](#). Mayo Clin Proc. 2016; 91 (11): 1645-1666. PubMed

## Related Information

[Acute Lymphoblastic Leukemia - ALL](#)

## Related Tests

[Leukemia/Lymphoma Phenotyping Evaluation by Flow Cytometry 3001780](#)

**Method:** Flow Cytometry

[Chromosome Analysis, Bone Marrow 2002292](#)

**Method:** Giemsa Band

[Chromosome Analysis, Bone Marrow with Reflex to Genomic Microarray 2007130](#)

**Method:** Giemsa Band/Genomic Microarray (Oligo-SNP array)

[Cytogenomic SNP Microarray - Oncology 2006325](#)

**Method:** Genomic Microarray (Oligo-SNP Array)

[Cytogenomic Molecular Inversion Probe Array, FFPE Tissue - Oncology 2010229](#)

**Method:** Molecular Inversion Probe Array

[Chromosome FISH, Interphase 2002298](#)

**Method:** Fluorescence in situ Hybridization (FISH)

[BCR-ABL1, Qualitative with Reflex to BCR-ABL1 Quantitative 2005010](#)

**Method:** Reverse Transcription Polymerase Chain Reaction

[TPMT and NUDT15 3001535](#)

**Method:** Polymerase Chain Reaction/Fluorescence Monitoring

[Thiopurine Methyltransferase, RBC 0092066](#)

**Method:** Enzymatic/Quantitative Liquid Chromatography-Tandem Mass Spectrometry

## Thiopurine Metabolites by LC-MS/MS 2014484

**Method:** Quantitative Liquid Chromatography/Tandem Mass Spectrometry

ARUP Laboratories is a nonprofit enterprise of the University of Utah and its Department of Pathology, 500 Chipeta Way, Salt Lake City, UT 84108  
(800) 522-2787 | (801) 583-2787 | aruplab.com | arupconsult.com  
Content Review July 2020 | Last Update August 2020

© 2021 ARUP Laboratories. All Rights Reserved.

Client Services - (800) 522-2787